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Jeroen P. Saeij 1*
1Department of Pathology, Microbiology and Immunology, University of California, Davis, Davis, CA, United States,
2Whitehead Institute for Biomedical Research, Cambridge, MA, United States, 3 Biology Department, Massachusetts
Institute of Technology, Cambridge, MA, United States
The Toxoplasma gondii parasitophorous vacuole membrane (PVM) offers protection from
the host immune system but is also a barrier for uptake of nutrients from the host.
Previously, we showed that GRA17 mediates the tachyzoite PVM permeability to small
molecules. During the conversion from tachyzoites to encysted bradyzoites, the PVM
become the cyst membrane that is the outer layer of the cyst wall. Little is known about
how small molecules, such as nutrients, enter cysts. To characterize GRA17’s role in
cysts, we deletedGRA17 in the type II ME49 cyst-forming strain. ME49∆gra17 parasites
have reduced growth and formed grossly enlarged “bubble vacuoles,” which have
reduced PVM small molecule permeability. ME49∆gra17 parasites formed cysts in vitro
at rates comparable to the wild-type, but the viability of the bradyzoites inside these cysts
was significantly reduced compared to wild-type bradyzoites. Genetic complementation
of ME49∆gra17 with GRA17 expressed from the endogenous or tachyzoite-specific
SAG1 promoter recovered the viability of bradyzoites. Complementation with the
bradyzoite-specific SRS9 promoter drastically increased the viability of bradyzoites,
demonstrating the importance of GRA17 in regulating bradyzoite viability inside cysts.
Mice infected with a high dose of ME49∆gra17 parasites did not contain parasites in their
brain nor did mice infected with ME49∆gra17 complemented with GRA17 expressed
from a bradyzoite-specific promoter. Our results suggest that the ME49∆gra17 strain
is avirulent and is cleared before it can reach the brain and that GRA17 not only plays
an important role during acute infections but is also needed for viability of bradyzoites
inside cysts.
Keywords: cyst wall, parasitophorous vacuole membrane permeability, bradyzoite, dense granule proteins,
Toxoplasma persistence
INTRODUCTION
Toxoplasma gondii is an apicomplexan protozoan parasite able to invade and establish infection
in any warm-blooded animal. It causes toxoplasmosis, and its prevalence in humans is ∼30%
(Robert-Gangneux and Dard, 2012). Toxoplasma has a complex life cycle and in the intermediate
host, which also comprises humans, has two different stages: tachyzoites, which are the rapidly
dividing forms that disseminate throughout the body and differentiate into bradyzoites, which are
the slowly dividing forms that reside in intracellular tissue cysts preferentially located inmuscle and
neuronal cells (Dubey et al., 1998). The chronic stages can last the entire life of the intermediate host
and the cysts determine transmission between the intermediate hosts by carnivorism (Sullivan and
Jeffers, 2012). Currently, there is no adequate treatment against the bradyzoite stage.
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Toxoplasma is auxotrophic for certain nutrients such as
purines, cholesterol and essential amino acids (Coppens, 2014).
The PVM is selective permeable allowing the charge-independent
diffusion of molecules up to 1.3 kDa (Schwab et al., 1994). The
PVM permeability pore is likely how many nutrients enter the
PV. The absorbance of nutrients that are delivered to the PV
is mediated by membrane transporters located in the plasma
membrane of the tachyzoites (Rajendran et al., 2017; Parker
et al., 2019). Toxoplasma secreted proteins from dense granules
(GRAs) play an important role in nutrient acquisition. Our group
recently showed that GRA17 and GRA23, which localize to the
PVM, mediate the permeability of the PVM to small molecules
(Gold et al., 2015). GRA17 and GRA23 are alpha-helical proteins
that have homology with the well-characterized Plasmodium
translocon protein EXP2 (de Koning-Ward et al., 2009). Deletion
ofGRA17 in tachyzoites generates swollen “bubble” vacuoles that
have decreased permeability to small molecules. The expression
of EXP2 in ∆gra17 parasites leads to the abrogation of the
phenotype, which suggested that EXP2 might also function as a
nutrient pore (Gold et al., 2015). Recently, it was confirmed that
P. falciparum EXP2 acts as a translocon for exported proteins but
also as a pore facilitating the transport of nutrients into the PV
(Garten et al., 2018; Ho et al., 2018).
Other dense granule proteins are involved in nutrient
acquisition in the tachyzoite stage, such as GRA2 which is
involved in ingestion and digestion of host cytosolic proteins
(Dou et al., 2014), and GRA6 and GRA2 which are involved
in the uptake of rab-positive vesicles derived from the secretory
system of the host cell (Romano et al., 2017). Additionally, GRA7
is responsible for the formation of an intravacuolar membrane
bridge named H.O.S.T (Host-Organelle Sequestering Tubulo-
structures) that is important for uptake of lysosome-derived
vesicles (Coppens et al., 2006). It is likely that the ingestion of
host proteins and uptake of host endo-lysosomal vesicles can
also provide nutrients to Toxoplasma. Dense granules also secrete
a homolog of mammalian lecithin:cholesterol Acyltransferase
(LCAT) into the PV space, an enzyme that digests cholesterol and
delivers free lipids to the parasite (Pszenny et al., 2016).
Compared to tachyzoites, bradyzoites have a slower
metabolism and part of the bradyzoite population is arrested in
the G0 phase (White et al., 2014). However, it was recently shown
that a significant percentage of bradyzoites are metabolically
active and divide along the course of infection thereby mediating
cyst growth (Watts et al., 2015). Tissue cysts contain an external
membrane that is derived from the PVM. A thick layer of O- and
N-glycosylated proteins is deposited and compacted beneath the
cyst membrane, making up the cyst wall (Lemgruber et al., 2011;
Tomita et al., 2013). There is evidence that this thick barrier is
permeable to molecules up to 10 kDa (Lemgruber et al., 2011),
which was demonstrated by pulse-chase experiments using cysts
isolated from mouse brain. Thus, small host-derived nutrients
might also enter the cyst.
Host-pathogen interactions during the bradyzoite infection
are poorly understood. As a tachyzoite, Toxoplasma recruits
mitochondria, endoplasmic reticulum (ER), Golgi complex and
endolysosomal vesicles to the PVM, and this rearrangement of
host organelles is related to immune evasion and nutrient uptake
(Sinai et al., 1997; Magno et al., 2005; Romano et al., 2008, 2013,
2017; Pernas et al., 2014, 2018; Lopez et al., 2015). Cysts are also
strongly associated with ER, Golgi complex and endolysosomal
vesicles, while host mitochondria were not observed near the
cyst membrane. Notably, type II strains are not able to recruit
mitochondria to the vicinity of the PVM (Paredes-Santos et al.,
2017) due to a lack of expression of the dense granule protein
MAF-1b (Pernas et al., 2014; English and Boyle, 2018). Even
though the proximity of host organelles with the cyst wall was
demonstrated, it is not known if this organization around the
cyst is related to nutrient acquisition by bradyzoites. The uptake
of host derived vesicles from Golgi complex and endo-lysosomal
system shown in tachyzoites (Coppens et al., 2006; Romano et al.,
2013, 2017) has not yet been characterized in the bradyzoite
stage. Thus, a better understanding of the metabolic needs of
bradyzoites could unveil pathways to be targeted with new
treatment strategies.
Bradyzoites are known to differ from tachyzoites in their
carbohydrate metabolism. The main source of its carbohydrates
is concentrated in amylopectin granules, present mostly
in bradyzoites. The enzymes responsible for carbohydrate
processing often have two isoforms that are stage specifically
regulated (Coppin et al., 2003). Recently it was shown that
autophagy also plays an important role in the viability and
persistence of bradyzoites, likely because they are nutrient
starved (Di Cristina et al., 2017).
In the present work we investigated the role of GRA17
in bradyzoite viability and persistence of cysts. We show
that deletion of GRA17 in the type II ME49 cyst-forming
strain leads to a defect in PVM permeability to a small
molecule. ME49∆gra17 bradyzoites isolated from in vitro cysts
are significantly less viable compared to wild-type bradyzoites.
ME49∆gra17 parasites are avirulent in mice and do not reach
the brain. Thus, GRA17-mediated PVM permeability plays an
important role in viability of both tachyzoites and bradyzoites.
MATERIALS AND METHODS
Ethics Statement
All animal experiments were performed in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and the
Animal Welfare Act, approved by the Institutional Animal Care
and Use Committee at the University of California, Davis (UC
Davis) (assurance number A-3433-01).
Host Cell, Parasites and Plaque Size
Assays
Human foreskin fibroblasts (HFFs) were used as host cells
and were cultured under standard conditions using Dulbecco
Modified Eagle Medium (DMEM) with 10% fetal bovine serum
(FBS). The Toxoplasma gondii strain used for gene deletion was
the type II (ME49) engineered to express RFP (a gift from Dr.
Michael Grigg). This strain was used to make our background
strain: ME49-RFP∆hxgprtCas9. The strain ME49-RFP was used
to knockout HXGPRT using single guide RNAs (sgRNAs)
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assembled by ligation of duplexed oligos into BsaI cut pU6-
Universal (Addgene plasmid #52694). The parasites were counter
selected with 6-thioxanthine (300µg/mL) and knockouts were
confirmed by PCR (all primers and sgRNAs are listed in
Table S1). To generate ME49 constitutively expressing Cas9,
ME49-RFP∆hxgprt parasites were transfected with a plasmid
containing a FLAG-tagged Cas9 and a decoy sgRNA (Sidik et al.,
2016), parasites were selected with chloramphenicol and Cas9
expression was confirmed by anti-FLAG Immunofluorescence
assay (IFA). ME49-RFP∆hxgprtCas9 was used in this work
for genetic manipulation and considered the wild-type strain.
Relative parasite growth rate was measured by plaque size
assays (Rosowski et al., 2011).
Generation of Parasite Strains
Individual GRA17 (TGME49_222170) knockout parasites were
generated using CRISPR-Cas9. sgRNA sequences targeting
GRA17 were cloned into the pSS013-Cas9 vector (Sidik
et al., 2014). Plasmids containing sgRNAs were co-transfected
with XhoI (New England Biolabs)-linearized pTKOatt, which
contains the HXGPRT selection cassette (Rosowski et al., 2011),
into wild-type parasites at a ratio 5:1 (sgRNAs: linearized
pTKOatt plasmid). After 24 h, the populations were selected
with mycophenolic acid (50µg/ml) and xanthine (50µg/ml)
and cloned by limiting dilution. Gene disruption was assessed
by PCR.
Complementation of the ME49∆gra17
Strain
Complementation of ME49∆gra17 parasites with GRA17
was done by integration of the complementation construct
into the uracil phosphoribosyltransferase locus (UPRT)
(TGME49_312480). The complementation construct consisted
of homology arms for the UPRT locus, stage-specific promoters
(see below), the coding sequence for GRA17 with a C-terminal
c-Myc tag and the 3′UTR region of GRA17. Complementation
constructs were made by Gibson assembly of the PCR products,
the homology arms of UPRT were present in the backbone
plasmid pUPRT::DHFR-D (Addgene plasmid #58528 Shen
et al., 2014. To drive the stage-specific expression of GRA17
we made constructs where GRA17 was expressed from the
following three promoters: (1) the endogenous GRA17 promoter
from −1,500 bp to ATG; (2) to promote the expression of
GRA17 only in the tachyzoite stage the promoter of SAG1
(TGME49_233460) from −1,500 bp to ATG; (3), to promote
the expression of GRA17 only in the bradyzoite stage the
promoter of SRS9 (TGME49_320190) was used (from −1,500
to ATG). ME49∆gra17 parasites were co-transfected with a
plasmid containing Cas9 and a sgRNA targeting the UPRT
locus and one of the complementation constructs described
above. The transfected parasites were selected in 10µM FUDR,
subcloned, and c-Myc positive clones were selected by IFA using
an antibody against the c-Myc tag (Thermo). The insertion
of the complementation construct in the UPRT locus was
confirmed by PCR.
In vitro Stage Differentiation
Briefly, HFFs monolayers were infected with T. gondii at a MOI
of 0.2 for 16 h after which the medium was changed to RPMI
(Gibco) buffered with Tricine at pH 8.1 complemented with 10%
of Fetal Bovine Serum, 2mM of L-glutamine and 10 U/ml of
penicillin and streptomycin. The infected cells were incubated at
37◦C and ambient CO2, an additional conversion assay was done
following the same procedures, but the incubation occurred at
37◦C and 5% CO2.
Staining of the Cyst Wall
Samples were fixed in 3% formaldehyde PBS (Phosphate buffered
saline) solution for 20min, blocked and permeabilized in 0.2%
Triton X-100, 3% Bovine Serum Albumin and 5% goat serum in
PBS for 45min, followed by incubation with Dolichos Biflorus
Agglutinin (DBA)-FITC or DBA-TRITC (Vector Laboratories)
10µg/ml in PBS for 1 h. The samples were mounted in ProLong
Gold Diamond and observed under an epifluorescence inverted
microscope Nikon (eclipse Ti-S; Nikon) connected to NIS-
Elements software (Nikon) and a digital camera (CoolSNAP EZ;
Roper Scientific).
Isolation and Viability Testing of in vitro
Bradyzoites
In vitro generated Bradyzoites were isolated from infected flasks
after 7 and 14 days by serial passages through needles of different
gauges (18G, 21G, 25G, and 30G) followed by 30min of pepsin
treatment at 37◦C (pepsin solution: 0.0026% of Pepsin-3500
units/mg, 170mM NaCl and 60mM HCl pH 1.7. After 30min
the solution was neutralized with an equal volume of 94mM
Na2CO3. The parasites were washed in media and counted; 5,000
parasites were plated in 24 well plates containing confluent HFFs.
The number of plaques were counted 9 days post infection (p.i.),
the relative percentage of plaque numbers was calculated by
normalization of the number of plaques present in the wild type
group set as 100%.
Live Cell Imaging of PVM Permeability
HFFs were grown on glass-bottom dark 24-well plates (Greiner
Bio-One) and infected with tachyzoites for 24 h in regular media.
The cells were washed with PBS and medium was replaced with
DMEM plus 10% FBS minus phenol red (GMPR) supplemented
with 10µM 5(6)-Carboxy-2′,7′-dichlorofluorescein diacetate
(CDCFDA) for 10min at 37◦C. CDCFDA was sequentially
diluted into GMPR from a 10mM DMSO solution. The dye-
containing media was removed, and the cells were washed
three times with PBS, replaced with GMPR, and were
immediately imaged.
Western Blotting
Intracellular samples of the complemented strains were subjected
to SDS-PAGE followed by Western blotting. Immunoblots were
probed with mouse anti-c-Myc (Thermo; 1:500), rabbit anti-
TgGRA7 (1:5,000–John Boothroyd Lab), in Odyssey LI-COR
blocking buffer (LI-COR Biosciences), followed by incubation
with IRDye 680-conjugated anti-rabbit IgG and IRDye 800-
conjugated anti-mouse IgG (LI-COR), each at 1:20,000 in PBS
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containing 0.5% BSA. The blots were washed in PBS and scanned
using an Odyssey CLx infrared imager (LI-COR). Images were
processed using Image Studio software (LI-COR).
In vivo Infection
For mouse infections, HFFs infected with the wild-type and
the knockout strains were mechanically lysed with 30G needles,
washed with PBS, and centrifuged at 582 g for 5min to pellet
any intact HFFs. The supernatant was subsequently centrifuged
at 933 g for 7min to collect tachyzoites and then diluted in
PBS and counted. For the survival assays, female CD-1 mice
(age 6–8 weeks, Charles River Laboratories) were infected
intraperitonially (i.p). with 1,250 tachyzoites of wild type and
ME49∆gra17::pSRS9-GRA17. Another two cohorts of mice were
infected with 106 and 103, 5 × 103, 1 × 104, 5 × 104,
and 105 tachyzoites of ME49∆gra17 or 105 tachyzoites of the
ME49∆gra17::pSRS9-GRA17 strain and monitored for survival
for 60 days. For all infections, parasite viability was assessed
by plaque assays, and all surviving mice were verified to be
seropositive for Toxoplasma. Mice with a body condition score
below 2 were euthanized and counted as dead in accordance with
institutional and federal regulations. All mice were maintained in
specific pathogen-free conditions.
In vivo Infection: Cyst Counting, Diagnostic
PCR and Serological Detection
At 60 days p.i., the mice were euthanized, and the brains were
harvested. Following homogenization of brains by passaging
though a 21-gauge needle, cysts were stained with FITC-
conjugated DBA after fixation with ice cold 100% methanol.
To detect the presence of parasites in the brain from infected
animals, genomic DNA of homogenized brains was isolated using
the Qiagen DNeasy Blood & Tissue Kit (Qiagen). Diagnostic
PCR targeting the multi-copy Toxoplasma B1 gene was
performed. Anti-Toxoplasma IgG response of infected animals,
was determined as described previously (Wang et al., 2019).
RESULTS
Deletion of GRA17 in the ME49 Strain
Decreases Tachyzoite Vacuole
Permeability
To understand the role of GRA17 in bradyzoites we generated
GRA17 knockout parasites in the type IIME49 strain (Figure S1).
We complemented theME49∆gra17 strain by expressingGRA17
from its endogenous promoter (ME49∆gra17::GRA17), from
the tachyzoite-specific SAG1 promoter (ME49∆gra17::pSAG1-
GRA17) and from the bradyzoite-specific SRS9 promoter
(ME49∆gra17::pSRS9-GRA17) (Figure S1).
The overall growth of tachyzoites of all the strains generated
was assessed by plaque assays. Consistent with our previously
published data for the RH∆gra17 strain (Gold et al., 2015),
we observed significantly smaller plaques for the ME49∆gra17
and ME49∆gra17::pSRS9-GRA17 strains that do not express
GRA17 as tachyzoites (Figure 1A). ME49∆gra17 parasites
complemented with GRA17 expressed from the endogenous
or the SAG1 promoter formed plaques that were almost
twice as large as plaques formed by wild-type parasites,
although this did not reach significance. We previously observed
that overexpression of GRA17 enhances parasite growth
(Gold et al., 2015).
A morphological characteristic of the phenotype of ∆gra17
parasites is the appearance of swollen PVs which we previously
dubbed “bubble” vacuoles (Gold et al., 2015). We saw a similar
phenotype in PVs formed by ME49∆gra17 tachyzoites. We
performed a quantification of bubble vacuoles in live cells
(Figure 1B) and observed that 50% of the ME49∆gra17 and
54% of the ME49∆gra17::pSRS9-GRA17 vacuoles were bubble
vacuoles. These data confirm that the lack of GRA17 expression
in tachyzoites leads to the generation of “bubble vacuoles.”
The stage-specific expression of GRA17 in the tachyzoite
stage was confirmed by IFA (Figure 1C), it is important to
note that the expression level from the endogenous promoter
was not as strong compared to expression from the SAG1
promoter therefore the exposure time for acquisition of
images for ME49∆gra17::GRA17 was doubled. Western
blotting also showed that GRA17 expression from the SAG1
promoter is higher compared to its expression from the
endogenous GRA17 promoter (Figure 1D). GRA17 expressed
by ME49∆gra17::GRA17 and ME49∆gra17::pSAG1-GRA17
tachyzoites was mainly localized to the PVM area while
ME49∆gra17::pSRS9-GRA17 did not express GRA17 as
tachyzoites (Figure 1C).
A characteristic of “bubble” vacuoles is the decreased
permeability to small molecules. To confirm this in the
ME49∆gra17 strain, we used the properties of the vital
dye 5-(and-6)-Carboxy-2′,7′-Dichlorofluorescein Diacetate
(CDCFDA), which is membrane permeable and non-fluorescent
until it enters living cells, where intracellular esterases convert
it into the fluorescent, membrane-impermeable 5-(and-6)-
Carboxy-2′,7′-Dichlorofluorescein. The molecular weight of the
CDCFDA fluorophore (445.2 Da) is less than the established size
exclusion limit of the Toxoplasma PVM (Schwab et al., 1994),
so we predicted that it should passively enter into the PV. As
expected, vacuoles of tachyzoites of ME49∆gra17 presented a
decrease in the permeability to dye where only 35% of vacuoles
were permeable (Figure 1E). The permeability is related with the
presence of the bubble phenotype, none of the bubble vacuoles
observed in this experiment were permeable to the dye.
ME49∆gra17 Conversion Into Cysts in vitro
Because the behavior of the type II strains was comparable
with the type I in the tachyzoite stage we sought to investigate
if the deletion of GRA17 would disrupt cyst formation in
vitro. All the strains generated in this study were able to
form cysts in vitro (Figures 2A–C). We observed that the
“bubble” vacuoles present in the tachyzoite stage converted
into “bubble cysts, which contained a cyst wall as determined
by DBA staining (Figure 2A). After performing in vitro
stage conversion for 5 days we observed that cysts from
the ME49∆gra17::GRA17, ME49∆gra17::pSAG1-GRA17, and
ME49∆gra17::pSRS9-GRA17 strains contained GRA17 in the
PVM and cyst wall area (Figure 2C). It is important to note
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FIGURE 1 | Characterization of ME49∆gra17 and complemented parasites. (A) Confluent monolayers of HFFs were infected with 500 tachyzoites of indicated strains
for 8 days after which the area of at least 25 plaques was measured and the mean area was normalized to the wild type. (B) Confluent monolayers infected at a MOI
of 2 for 48 h were used for the quantification of “bubble” vacuoles in 10 fields at 40X magnification. At least 50 vacuoles were counted for each replicate. A
representative image of a “bubble” vacuole formed by ∆gra17 parasites is shown, RFP (Red) bradyzoites, GRA2 (Green) IVN and PVM. (C) IFA of c-Myc-tagged
GRA17 in the complemented strains during the tachyzoite stage 72 h p.i. Complemented strains are: ∆gra17::GRA17, ∆gra17::pSAG1-GRA17,
∆gra17::pSRS9-GRA17. Inset) IFA merged with phase showing bubble vacuole. (D) Western blot of tachyzoite lysate 48 h p.i. of the indicated strains detecting
c-Myc-tagged GRA17 (red) and GRA7 (green) as a loading control. (E) HFFs were infected with wild type or ∆gra17 parasites and 24h p.i. CDCFDA was added for
10min after which it was washed away. At least 50 PVs/well were counted and classified as CDCFDA-positive or negative. A representative image of a wild-type
vacuole with normal permeability to CDCFDA and a ∆gra17 bubble vacuoles with reduced permeability to CDCFDA is shown. Bars are averages from biological
replicates (n = 5 for A and n = 3 for B and C), error bars represent SD, unpaired Student’s t-tests were performed comparing each strain with the wild type to assess
statistical significance (****p < 0.0001, ***p = 0.0002, **p = 0.0015).
that the expression level from the endogenous promoter was
not as strong compared to expression from the SAG1 promoter
therefore the exposure time for acquisition of images for
ME49∆gra17::GRA17 was doubled. We observed a significant
decrease in the percentage of cysts that are “bubble” cysts in the
ME49∆gra17::pSRS9-GRA17 strain after conversion suggesting
that GRA17 is able to correctly traffic to the cyst wall membrane
and perform its function (Figures 2B,D). The quantification of
cysts and PVs at day 5 after conversion showed that the ∆gra17
strain had an enhanced conversion rate compared to wild-type
parasites (Figure 2C). Possibly the decreased PVM permeability
in this strain leads to decreased nutrient availability and higher
conversion rates. These data show that the absence of GRA17
does not disrupt the conversion ability of Toxoplasma and in fact
might enhance the conversion to encysted bradyzoites.
Tachyzoite Expression of GRA17 Is
Essential for Parasites to Reach the Brain
and Form Cysts in vivo
The role of GRA17 in cyst formation and persistence in vivo
was explored by infecting mice with wild type, ME49∆gra17,
ME49∆gra17::pSAG1-GRA17 andME49∆gra17::pSRS9-GRA17
parasites. The animals were followed for 21 days, and the
presence of cysts in the brain was evaluated by IFA and
PCR. Due to high virulence all the animals infected with 1
× 103 wild-type parasites succumbed to the infection before
the time frame for cyst formation (Figure 3A). The animals
infected with ME49∆gra17 survived doses up to 1 × 105
parasites but succumbed to a dose of 1 × 106 parasites
(Figure 3A). Surviving animals did not contain cysts in the
brain (Figure 3C); however, the animals were infected as they
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FIGURE 2 | In vitro cyst formation of ME49∆gra17 and complemented strainsConfluent HFF were infected with indicated strains at a MOI of 0.2. Cyst conversions
was stimulated using ambient CO2 and pH 8.1 for 5 days. (A) Samples were fixed and permeabilized with methanol, the cyst wall was stained with DBA-FITC, GRA17
was detected with a c-Myc antibody, and parasites were stained with a GRA2 antibody. Inset) higher magnification showing DBA-positive cyst wall. (B) At least 100
vacuoles for each experiment were classified as DBA-positives or DBA-negative. Each bar represents the average plus SD of biological replicates (n = 4). Significant
differences in the conversion ratio between wild-type and the different strains was assessed by Student’s t-test (p = 0.00012). (C) Samples were fixed with
formaldehyde, the cyst wall was stained with DBA-TRITC, GRA17 was detected with a c-Myc antibody, and parasites expressed RFP. Inset) higher magnification
showing DBA-positive cyst wall. (D) At least 100 cysts for each experiment were classified as regular or “bubble” cysts. Each bar represents the average plus SD of
biological replicates (n = 4). Significant differences in the number of “bubble” cysts between ∆gra17 and ∆gra17::pSRS9-GRA17 was assessed by Student’s
t-test (p = 0.002).
had antibodies against T. gondii in the serum (Figure S2). In
the group infected with 1 × 103 ME49∆gra17::pSAG1-GRA17,
30% of the animals succumbed to the infection (Figure 3B),
in the remaining animals an average of 550 cysts/brain were
found (Figures 3C,D) and these cysts contained GRA17 in the
cyst wall membrane (Figure 3D). Mice infected with 1 × 105
ME49∆gra17::pSRS9-GRA17 survived (Figure 3B) and did not
contain brain cysts (Figure 3C). Altogether these results indicate
that GRA17 expression is important for acute virulence, and
absence of tachyzoite GRA17 expression results in a failure of
ME49∆gra17 parasites to reach the brain and form cysts.
ME49∆gra17 in vitro Generated Cysts
Contain Bradyzoites With Decreased
Viability
Because GRA17 is a mediator of PVM permeability and is likely
involved in the diffusion of small molecules such as nutrients
into the cyst, we hypothesized that GRA17 is important for
maintenance of cysts and viability of bradyzoites inside cysts.
To address this, we performed in vitro differentiation for
1 or 2 weeks, counted the relative number of DBA-positive
vacuoles and assessed the viability of the bradyzoites inside cysts
by plaque assays. To make sure we only assessed the viability
of bradyzoites, without any contamination from tachyzoites,
the infected cultures were treated with pepsin to eliminate
any remaining tachyzoites. The plaque assays after conversions
showed a significant decrease in the viability of ME49∆gra17
bradyzoites (Figures 4C,D). Tachyzoites treated with pepsin did
not form plaques indicating that pepsin treatment was effective
in killing tachyzoites (not shown). These results indicate that
GRA17 plays a role in bradyzoite survival inside cysts. We were
unable to use our complemented strains to demonstrate that
this phenotype can be rescued by expression of GRA17 as the
disruption of the UPRT gene in the complemented parasites
drastically reduced the viability of the bradyzoites (not shown).
The disruption ofUPRT leads to the disruption of the pyrimidine
salvage pathway and in the absence of CO2 the parasites are
unable to synthetize de novo pyrimidine because the enzymes
in the de novo synthesis pathway are CO2 dependent. The
conversion ratio between day 7 and day 14 did not change
significantly between the strains (Figure 4A). However, all strains
tested had an overall decrease in the number of vacuoles per field
14 days after conversion (Figure 4B).
To overcome the lack of viability of the complemented
strains under ambient CO2 conditions, we carried out the
conversion assays under 5% CO2 and evaluated the viability of
the bradyzoites after 7 days. In this alternative set up, bradyzoites
from the ME49∆gra17::GRA17 and ME49∆gra17::pSAG1-
GRA17 strain showed a comparable recovery in viability
when compared to the wild type strain. Cysts from the
ME49∆gra17::pSRS9-GRA17 strain contained bradyzoites that
were significantly more viable when compared with wild-type
bradyzoites (Figure 4D). These results indicate that although the
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FIGURE 3 | Deletion of GRA17 impacts parasite virulence in the ME49 strain. Female CD-1 mice (age 6 to 8 weeks) were i.p. infected with different doses of
tachyzoites from the indicated strains and survival was monitored. (A) Mice were infected with 1,250 tachyzoites of wild type (n = 5), or 1 × 106 tachyzoites of
∆gra17 (n = 5) and a range of 1 × 103; 5 × 103; 1 × 104; 5 × 104; 1 × 105 (n = 5 one animal/dose). (B) Mice were infected with 1,250 tachyzoite of
∆gra17::pSAG1-GRA17 or 1x105 tachyzoites ∆gra17::pSRS9+GRA17. (C) 21 p.i. mice were euthanized, and the number of cysts present in the brain was
determined by DBA staining. Dots represent the average cyst numbers in brains from 2 different animals. (D) Representative image detecting c-Myc-tagged GRA17 in
tissues cysts isolated from brain infected with ∆gra17::pSAG1-GRA17.
expression of GRA17 in tachyzoites is sufficient for bradyzoite
viability, the overexpression of GRA17 in the bradyzoite stage
positively impacts the viability of in vitro generated bradyzoites
likely by mediating nutrient traffic through the cyst wall.
Altogether these results indicate that the deletion of GRA17
decreases the viability of the bradyzoites over time and that
complementation strategies using the UPRT locus are not
suitable to address viability of bradyzoites under long in vitro
conversions under low CO2 conditions.
DISCUSSION
The chronic stage of toxoplasmosis is marked by the presence
of intracellular cysts in neuronal and muscle tissue and is
responsible for most of the cases of reactivation in HIV patients
causing deaths and serious complications due to encephalitis
(Porter and Sande, 1992). Stage conversion and persistence of
cysts in intermediate hosts is a key step for long term infection
of Toxoplasma (Jeffers et al., 2018). The mechanisms by which
bradyzoites survive and obtain small molecules, such as nutrients,
from the host is poorly understood. We previously showed that
GRA17-mediated PVM permeability to small molecules is an
important feature for in vivo virulence (Gold et al., 2015). The
reduced growth of ME49∆gra17 tachyzoites observed in this
study was consistent with our previously published data for the
RH∆gra17 strain (Gold et al., 2015) and similarly we observed
an increased growth rate of ME49 strains overexpressing GRA17.
Like in the RH∆gra17 strain, the presence of bubbles vacuoles
was also observed in ME49∆gra17 and was strongly correlated
with a decrease in PVM permeability to small molecules and
the bubble PVs persisted as bubble cysts. We successfully
complemented the ME49∆gra17 parasites by integration of
GRA17 expressed from the endogenous and from stage-specific
promoters in theUPRT locus and as expected GRA17 was located
in the cyst wall membrane area.
in vivo studies showed that expression levels of GRA17
decreased in bradyzoites from cysts isolated from brains
of infected mice (Pittman et al., 2014), however in vitro
data did not show a difference in expression between
the tachyzoite and bradyzoite stages (Fritz et al., 2012).
Recently, data on single cell RNA sequencing and bulk RNA
sequencing of cell sorted purified bradyzoites did not detect a
difference in the expression of GRA17 when compared with
tachyzoites (Waldman et al., 2019).
It is well-established that Toxoplasma starvation of nutrients
such as arginine and pyrimidine is a trigger for in vitro conversion
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FIGURE 4 | GRA17 is important for bradyzoite viability of the ME49 strain. Confluent monolayers of HFF were infected with indicated strains at a MOI of 0.2 and
incubated under stage-conversion conditions for 7 or 14 days. (A) The samples were fixed and at least 50 vacuoles were classified as DBA-positives or DBA-negative.
(B) The average number of vacuoles per field were counted (P < 0.0001). (C) Bradyzoites were isolated from the 7- and 14-day-old in vitro cysts that were treated
with pepsin to kill all tachyzoites. Confluent monolayers of HFFs were infected with 5 × 103 bradyzoites and 8 days later the number of plaques formed were counted
and the average number of plaques was normalized to wild type. Bars represents the averages of biological replicates (n = 4) and error bars represent SD. Unpaired
Student’s t-tests were performed comparing each strain with the wild type to assess statistical significance. ***p = 0.00012. (D) As in (C) but bradyzoites were
isolated from the 7-day-old in vitro cysts switched under 5% of CO2. Bars represents the averages of biological replicates (n = 3) and error bars represent SD.
Unpaired Student’s t-tests were performed comparing each strain with the wild type to assess statistical significance. ***p = 0.00017, **p = 0.0041.
(Jeffers et al., 2018). Therefore, the increased conversion rate
of ME49∆gra17 parasites was likely due to reduced availability
of nutrients. Our data suggest that GRA17 also mediates cyst
wall membrane permeability to small molecules as ME49∆gra17
bradyzoites were significantly less viable compared to wild-type
parasites. We recently showed, using single cell RNA sequencing,
that bradyzoites are replicating and 40% of bradyzoites are
in the S/M phase of the cell cycle and therefore likely need
nutrients (Waldman et al., 2019). Although the molecules
transported through the GRA17 permeability pores remain to
be characterized, it is clear that they play a role in maintaining
bradyzoites viability. Other nutrient processing related proteins
such as Cathepsin-L and the Toxoplasma chloroquine resistance
transporter, which are located in Toxoplasma’s lysosomal-like
vacuolar compartment (VAC), were shown to be important for
the viability of bradyzoites in vitro and in vivo, but these did not
affect the ability of the parasites to reach the brain and convert
into tissue cysts (Holpert et al., 2006; Di Cristina et al., 2017;
Kannan et al., 2019).
During in vivo infection lack of GRA17 expression in
ME49∆gra17 and ME49∆gra17::pSRS9-GRA17 parasites during
the tachyzoite stage had a huge impact on virulence, which
likely prevented these parasites from reaching the brain and
form cysts. Complementation of ∆gra17 parasites with GRA17
expressed from a bradyzoite promoter did not rescue the
complete avirulence of∆gra17 parasites.
The genomic complementation of GRA17 in the UPRT locus
and the deletion of UPRT has been used to enhance in vitro
conversion of RH strain parasites under ambient CO2 conditions
(Bohne and Roos, 1997). The combination of low levels of CO2,
disrupting the de novo synthesis of pyrimidine, and the absence
of the UPRT gene, responsible for salvage of pyrimidine, likely
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leads to starvation for this important nucleoside. This might
initially trigger cyst formation in vitro in the fast-growing type
I RH strain but here we show that it also strongly disrupts the
viability of bradyzoites inside cysts. In conclusion, the use of the
UPRT locus for genomic complementation with the purpose of
studying bradyzoite biology under low CO2 conditions is not
recommended. Thus, confirm the role of GRA17 in the viability
of the bradyzoites, the in vitro conversions were performed under
5% of CO2 allowed us to confirm a role for GRA17 in the viability
of bradyzoites; recovery of bradyzoite viability was observed for
all the complemented strains where GRA17 was expressed from
endogenous and stage-specific promoters.
The use of a tachyzoite-specific promoter led to expression
of GRA17 in tachyzoites and localization of GRA17 in the
cyst wall after stage conversion. Because SAG1 is known to
be strongly down regulated during the chronic stage (Pittman
et al., 2014; Waldman et al., 2019), the deposition of GRA17
on the PVM likely happened during the tachyzoite stage and
the protein was kept on the PVM that turned into the cyst
membrane. Possibly the stability and maintenance of certain
GRA proteins deposited in the PVM as tachyzoites is important
for the survival and persistence of cysts during the chronic stage.
Recently, proteomic analysis of cyst wall components showed
that GRA17 is one of the components of the cyst wall (Tu et al.,
2019). In this study two other dense granule proteins, CST2 and
CST3, were also characterized as major components of the cyst
wall, however, these proteins are also relatively highly expressed
in the tachyzoite stage and it is therefore likely that these
proteins were already deposited in the PVM before parasites were
converted into cysts. Further studies are needed to understand
the kinetics of dense granule protein deposition into PVM and
cyst wall membrane.
It is important to note that when GRA17 was expressed by
the bradyzoite-specific SRS9 promoter it dramatically increased
the viability of bradyzoite inside cysts. This suggests that the
endogenous expression level of GRA17 by bradyzoites is not
optimal and that enhanced expression of GRA17 by bradyzoites
likely leads to increased trafficking of nutrients through the cyst
wall membrane thereby sustaining bradyzoite viability.
∆gra17 “bubble cysts” contained a normal DBA-positive
cyst wall underneath the cyst wall membrane. How cyst wall
components correctly traffic through the large PV space of
∆gra17 parasites to reach the cyst wall membrane is unknown
but it is likely an active trafficking system must exist that traffics
proteins secreted beyond the parasite plasma membrane to the
correct final destination. The disappearance of “bubble cysts”
in ∆gra17 parasites complemented with GRA17 expressed from
the bradyzoite-specific SRS9 promoter suggests that GRA17
can traffic through the cyst wall and correctly perform its
function in the PVM. Additionally the export of parasite-derived
proteins across the PVM is important to manipulate the host
cell, during the tachyzoite stage (Hakimi and Bougdour, 2015;
Franco et al., 2016).We recently showed that GRA16 andGRA24,
two Toxoplasma secreted proteins that are exported to the host
nucleus during the tachyzoite stage, are retained inside cysts and
accumulate in the cyst wall membrane (Krishnamurthy and Saeij,
2018). It was recently shown that kinase activity of ROP17, which
is a rhoptry kinase localized to the cytoplasmic part of the PVM, is
needed for export of GRAs beyond the PVM (Panas et al., 2019).
This suggests that ROP17 phosphorylates a component of the
MYR1/2/3 translocon and that this phosphorylation is needed
for the correct functioning of the translocon. Because ROPs are
only secreted during invasion it is likely that a gradual decrease
of ROP17 on the PVM, e.g. during long in vitro conversion
experiments or in vivo in cysts, leads to a lack of phosphorylation
of the translocon and a defect in GRA export beyond the PVM.
This likely explains why exported GRAs, such as GRA16 and
GRA24, do not traffic to their correct location while others, such
as GRA17, do.
In conclusion, our work shows that GRA17 likely plays a role
in nutrient uptake involved in the viability of bradyzoites during
the chronic stage. Further investigations into how bradyzoites
gain access to host-derived nutrients across the barrier of the
cyst wall and cyst wall membrane are needed and might lead to
effective drug targets for this stage that is still untreatable and
responsible from the majority of the cases of reactivation, death
and neurological complications.
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of the UPRT locus (P4+P5) preserved in the wild type and the presence of the
insertion of the repair template in the locus (P4+P6).
Figure S2 | Mice infected with ME49∆gra17 seroconverted but had no parasites
in the brain. (A) Anti-T. gondii IgG antibodies present in the plasma of mice at day
60 p.i. with ∆gra17. (B) PCR to detect the multi-copy T. gondii B1 gene in
genomic DNA isolated from mouse brains infected with ∆gra17.
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